安胃疡胶囊辅助治疗消化性溃疡的实践与评估
|
摘要
目的:探讨安胃疡胶囊辅助治疗消化性溃疡的实践与评估。方法:选取2017年10月-2018年10月于本院就诊的消化性溃疡患者84例,按照随机数字表法将患者分为试验组(n=42)和对照组(n=42)。所有患者均进行四联疗法,试验组患者在此基础上服用安胃疡胶囊辅助治疗,两组均连续治疗4周。治疗结束后,观察比较两组患者的临床疗效、幽门螺杆菌(Hp)清除率、血清学指标及不良反应发生率。结果:试验组的总有效率为95.24%,高于对照组的76.19%,差异有统计学意义(P<0.05)。试验组Hp清除率为92.86%,高于对照组的71.43%,差异有统计学意义(P<0.05)。与治疗前比较,两组患者治疗后血清ET、IL-6、TNF-α水平均降低,血清NO、VEGF水平均升高,差异均有统计学意义(P<0.05);且试验组这些观察指标的改善程度均优于对照组(P<0.05)。治疗后,试验组患者的CD4~+T、CD4~+T/CD8~+T均显著高于对照组(P<0.05),CD8~+T显著低于对照组(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论:安胃疡胶囊辅助治疗消化性溃疡可有效增强临床效果,提高Hp清除率,改善血清细胞因子水平,提高患者免疫力且不良反应轻微,具有较好的临床推广应用价值。
Objective:To explore the practice and evaluation of Anweiyang Capsule in the treatment of peptic ulcer.Method:84 patients with peptic ulcer who were treated in our hospital from October 2017 to October2018 were selected,they were divided into experimental group(n=42)and control group(n=42)according to random number table method.All patients were given quadruple therapy,the experimental group was given Anweiyang Capsule as adjuvant therapy on this basis,and the two groups were treated continuously for 4 weeks.After treatment,the clinical efficacy,clearance rate of Helicobacter pylori(Hp),serological indicators and incidence of adverse reactions were observed and compared between the two groups.Result:The total effective rate of the experimental group was 95.24%,higher than 76.19% of the control group,the difference was statistically significant(P<0.05).The Hp clearance rate in the experimental group was 92.86%,higher than 71.43% in the control group,the difference was statistically significant(P<0.05).Compared with before treatment,serum ET,IL-6,TNF-α levels were all decreased and serum NO and VEGF levels were all increased in the two groups after treatment,with statistically significant differences(P<0.05);and the improvement degree of these observation indicators in the experimental group were better than those in the control group(P<0.05).After treatment,CD4~+ T, CD4~+ T/CD8~+ T in the experimental group were significantly higher than those in the control group(P<0.05),and CD8~+ T was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anweiyang Capsule as an adjuvant treatment for peptic ulcer can effectively enhance the clinical effect,improve the clearance rate of Hp,improve the level of serum cytokines,improve the immunity of patients and the adverse reactions is mild,and has good clinical application value.
Objective:To explore the practice and evaluation of Anweiyang Capsule in the treatment of peptic ulcer.Method:84 patients with peptic ulcer who were treated in our hospital from October 2017 to October2018 were selected,they were divided into experimental group(n=42)and control group(n=42)according to random number table method.All patients were given quadruple therapy,the experimental group was given Anweiyang Capsule as adjuvant therapy on this basis,and the two groups were treated continuously for 4 weeks.After treatment,the clinical efficacy,clearance rate of Helicobacter pylori(Hp),serological indicators and incidence of adverse reactions were observed and compared between the two groups.Result:The total effective rate of the experimental group was 95.24%,higher than 76.19% of the control group,the difference was statistically significant(P<0.05).The Hp clearance rate in the experimental group was 92.86%,higher than 71.43% in the control group,the difference was statistically significant(P<0.05).Compared with before treatment,serum ET,IL-6,TNF-α levels were all decreased and serum NO and VEGF levels were all increased in the two groups after treatment,with statistically significant differences(P<0.05);and the improvement degree of these observation indicators in the experimental group were better than those in the control group(P<0.05).After treatment,CD4~+ T, CD4~+ T/CD8~+ T in the experimental group were significantly higher than those in the control group(P<0.05),and CD8~+ T was significantly lower than that in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anweiyang Capsule as an adjuvant treatment for peptic ulcer can effectively enhance the clinical effect,improve the clearance rate of Hp,improve the level of serum cytokines,improve the immunity of patients and the adverse reactions is mild,and has good clinical application value.
引文
[1]中华消化杂志编委会.消化性溃疡诊断与治疗规范(2016年,西安)[J].中华消化杂志,2016,36(8):508-513.
[2]张馨,邓茂林,吴玲霞,等.三联疗法与胃复春联合治疗幽门螺杆菌阳性胃溃疡的疗效评估[J].现代生物医学进展,2016,16(10):1937-1939.
[3]焉石.自拟健脾益胃汤联合西药常规治疗消化性溃疡临床研究[J].中医药信息,2017,34(2):99-101.
[4]袁耀宗.消化性溃疡病诊断与治疗规范[J].全科医学临床与教育,2016,17(3):243-246.
[5]李大威,王振东.安胃疡胶囊治疗胃溃疡的临床疗效[J].中国处方药,2017,15(4):105-106.
[6]丁秀婷.安胃疡胶囊联合四联疗法治Hp感染200例临床观察[J].河北医学,2017,23(5):835-837.
[7]谢代彬,王梅,贾雁平,等.消化性溃疡合并幽门螺杆菌感染患儿奥美拉唑四联疗法治疗效果分析[J].中华医院感染学杂志,2016,26(5):1146-1148.
[8]赵兴彬.四联疗法在消化性溃疡合并幽门螺杆菌感染治疗中的应用分析[J].中国实用医药,2016,11(15):179-184.
[9]沈璐.四联疗法治疗消化性溃疡合并幽门螺杆菌感染疗效分析[J].基层医学论坛,2017,21(10):1191-1192.
[10]谭细生,李刚,王新仁,等.泮托拉唑治疗消化性溃疡合并上消化道出血的临床疗效观察[J].中国现代医生,2016,54(2):30-32.
[11]秦臻,吴成,陈苗苗,等.幽门螺杆菌感染对消化性溃疡患儿免疫功能的影响[J].锦州医科大学学报,2016,37(2):58-60.
[12]赵玉东.雷贝拉唑联合安胃疡胶囊治疗消化性溃疡的疗效及对血浆胃泌素、胃动素水平的影响[J].慢性病学杂志,2018,22(2):644-645.
[13]周娥.安胃疡胶囊联合四联疗法治疗难治性消化性溃疡的临床研究[J].现代药物与临床,2016,31(8):1197-1200.
[14]杨剑,吴万桂.安胃疡胶囊联合西医四联疗法治疗幽门螺杆菌阳性消化性溃疡疗效观察[J].现代中西医结合杂志,2018,27(20):27-28.
[15]毛军民,石镇东.匡清清,等.调和解毒法联合四联疗法治疗幽门螺杆菌阳性消化性溃疡的临床研究[J].现代中西医结合杂志,2016,25(19):2060-2062.
[16]吴雅鋆,黄永德.幽门螺杆菌感染与消化性溃疡患者血清中IL-6、IL-8、IL-2相关性临床观察[J].临床军医杂志,2017,45(1):38-41.
[17]林忠顺,吕国恩,吕俊廷,等.自然杀伤T细胞在幽门螺旋杆菌阳性消化性溃疡患者中的水平与临床意义[J].检验医学与临床,2016,13(21):3023-3025.
[18]曹云,张雯.消化性溃疡细胞因子水平与相关因素分析[J].中国民间疗法,2018,22(1):319-320.
[19]王春.气滞胃痛颗粒联合叶酸对Hp阳性慢性萎缩性胃炎患者血清胃泌素17、胃蛋白酶原及免疫功能的影响[J].湖北中医药大学学报,2018,14(2):41-42.
[2]张馨,邓茂林,吴玲霞,等.三联疗法与胃复春联合治疗幽门螺杆菌阳性胃溃疡的疗效评估[J].现代生物医学进展,2016,16(10):1937-1939.
[3]焉石.自拟健脾益胃汤联合西药常规治疗消化性溃疡临床研究[J].中医药信息,2017,34(2):99-101.
[4]袁耀宗.消化性溃疡病诊断与治疗规范[J].全科医学临床与教育,2016,17(3):243-246.
[5]李大威,王振东.安胃疡胶囊治疗胃溃疡的临床疗效[J].中国处方药,2017,15(4):105-106.
[6]丁秀婷.安胃疡胶囊联合四联疗法治Hp感染200例临床观察[J].河北医学,2017,23(5):835-837.
[7]谢代彬,王梅,贾雁平,等.消化性溃疡合并幽门螺杆菌感染患儿奥美拉唑四联疗法治疗效果分析[J].中华医院感染学杂志,2016,26(5):1146-1148.
[8]赵兴彬.四联疗法在消化性溃疡合并幽门螺杆菌感染治疗中的应用分析[J].中国实用医药,2016,11(15):179-184.
[9]沈璐.四联疗法治疗消化性溃疡合并幽门螺杆菌感染疗效分析[J].基层医学论坛,2017,21(10):1191-1192.
[10]谭细生,李刚,王新仁,等.泮托拉唑治疗消化性溃疡合并上消化道出血的临床疗效观察[J].中国现代医生,2016,54(2):30-32.
[11]秦臻,吴成,陈苗苗,等.幽门螺杆菌感染对消化性溃疡患儿免疫功能的影响[J].锦州医科大学学报,2016,37(2):58-60.
[12]赵玉东.雷贝拉唑联合安胃疡胶囊治疗消化性溃疡的疗效及对血浆胃泌素、胃动素水平的影响[J].慢性病学杂志,2018,22(2):644-645.
[13]周娥.安胃疡胶囊联合四联疗法治疗难治性消化性溃疡的临床研究[J].现代药物与临床,2016,31(8):1197-1200.
[14]杨剑,吴万桂.安胃疡胶囊联合西医四联疗法治疗幽门螺杆菌阳性消化性溃疡疗效观察[J].现代中西医结合杂志,2018,27(20):27-28.
[15]毛军民,石镇东.匡清清,等.调和解毒法联合四联疗法治疗幽门螺杆菌阳性消化性溃疡的临床研究[J].现代中西医结合杂志,2016,25(19):2060-2062.
[16]吴雅鋆,黄永德.幽门螺杆菌感染与消化性溃疡患者血清中IL-6、IL-8、IL-2相关性临床观察[J].临床军医杂志,2017,45(1):38-41.
[17]林忠顺,吕国恩,吕俊廷,等.自然杀伤T细胞在幽门螺旋杆菌阳性消化性溃疡患者中的水平与临床意义[J].检验医学与临床,2016,13(21):3023-3025.
[18]曹云,张雯.消化性溃疡细胞因子水平与相关因素分析[J].中国民间疗法,2018,22(1):319-320.
[19]王春.气滞胃痛颗粒联合叶酸对Hp阳性慢性萎缩性胃炎患者血清胃泌素17、胃蛋白酶原及免疫功能的影响[J].湖北中医药大学学报,2018,14(2):41-42.